The hallucinogenic compound psilocybin is undergoing a renaissance-not as a recreational drug but as a potential treatment for mental health conditions. We follow the journey of one participant of a scientific study into the psychedelic drug's effect on depression.
Learn more about your ad choices. Visit megaphone.fm/adchoices

The hallucinogenic compound psilocybin is undergoing a renaissance-not as a recreational drug but as a potential treatment for mental health conditions. We follow the journey of one participant of a scientific study into the psychedelic drug's effect on depression. Learn more about your ad choices. Visit megaphone.fm/adchoices

How Psychedelic Drugs Are Making A Comeback To Treat Depression

WSJ’s Bold Names brings you conversations with the leaders of the bold-named companies featured in the pages of The Wall Street Journal. Hosts Tim Higgins and Christopher Mims speak to CEOs and business leaders in interviews that challenge conventional wisdom and take you inside the decisions being made in the C-suite and beyond.

Share How Psychedelic Drugs Are Making A Comeback To Treat Depression

Sign up to save your podcasts

How Psychedelic Drugs Are Making A Comeback To Treat Depression

How Psychedelic Drugs Are Making A Comeback To Treat Depression

More shows like Bold Names

WSJ Opinion: Potomac Watch

WSJ Your Money Briefing

Exchanges

WSJ What’s News

Bloomberg Businessweek

WSJ Tech News Briefing

The a16z Show

WSJ Minute Briefing

The Indicator from Planet Money

Wall Street Breakfast

Thoughts on the Market

The Journal.

Barron's Streetwise

Barron's Live

Bad Bets

WSJ Opinion: Free Expression

As We Work

WSJ's Take On the Week